Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REPRONEX vs CHORIONIC GONADOTROPIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Induction of ovulation in oligo-ovulatory or anovulatory women with functional hypothalamic-pituitary dysfunction (WHO Group II),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
REPRONEX is a glycoprotein hormone that is cleared primarily by the liver and kidneys. The metabolic pathways involve proteolytic degradation. The terminal half-life is approximately 4-12 hours after subcutaneous administration.
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Approximately 10%; mainly albumin
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
0.2-0.5 L/kg; reflects distribution primarily in extracellular fluid
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
SC/IM: nearly 100%
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
Not recommended for use in pediatric patients (safety and efficacy not established).
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased risk of thromboembolic events.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
REPRONEX should only be used by physicians who are experienced in infertility treatment and capable of monitoring ovarian response. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and potentially fatal. Multiple births have been reported.
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
Risk of ovarian hyperstimulation syndrome (OHSS), which can be severe,Risk of multiple gestation,Thromboembolic events,Ovarian torsion,Pulmonary complications (e.g., atelectasis, adult respiratory distress syndrome)
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,An organic intracranial lesion (e.g., pituitary tumor),Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement of unknown etiology,Pregnancy,Hypersensitivity to urofollitropin or any component
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
No specific food interactions documented. Maintain adequate hydration to reduce OHSS risk. Avoid excessive alcohol or caffeine as they may affect fertility.
No known food interactions.
REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indication for use during pregnancy, as it is used for ovulation induction in infertility. If used inadvertently, there is a risk of multiple gestations and potential for congenital anomalies, but no specific teratogenic pattern has been established. Use is contraindicated in pregnant women.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
It is unknown whether menotropins are excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
REPRONEX is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as it is not indicated for use during pregnancy. Pharmacokinetic changes in pregnancy do not apply because the drug is not administered during pregnancy.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
REPRONEX (menotropins) is a gonadotropin preparation containing FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize ovarian hyperstimulation syndrome (OHSS) risk. Avoid use in primary ovarian failure. Administer intramuscularly; rotate injection sites. Concomitant h CG is required for final follicular maturation and ovulation trigger.
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
Store REPRONEX in the refrigerator and protect from light.,Administer exactly as prescribed; do not change dose or schedule.,You may experience bloating, pelvic discomfort, or mood swings; report severe abdominal pain, nausea, or rapid weight gain (signs of OHSS) immediately.,Multiple pregnancy is possible; discuss risks with your doctor.,Use barrier contraception until instructed to attempt conception.,Do not drive or operate machinery if dizziness or visual disturbances occur.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REPRONEX vs CHORIONIC GONADOTROPIN, answered by our medical review team.
REPRONEX is a Gonadotropin that works by REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.. CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REPRONEX and CHORIONIC GONADOTROPIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REPRONEX is: Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.. The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REPRONEX and CHORIONIC GONADOTROPIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REPRONEX is classified as Category C. REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indica. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.